LARVOL is pleased to present a moderated discussion with top oncologists following ASCO's Annual Meeting 2021. In the video below, Dr. Eric Whitman, Dr. Allison Betof Warner, and Dr. Jason Luke discuss the practice-changing impact of ASCO presentations in melanoma.
On June 6, 2021, LARVOL hosted an Oncology Panel to discuss the top melanoma clinical trial abstracts presented during the American Society of Clinical Oncology (ASCO) Annual Meeting 2021, held on June 4-8,2021. Dr. Eric Whitman from the Atlantic Health System Cancer Care moderated a discussion between Dr. Allison Betof Warner from Memorial Sloan Kettering Cancer Center and Dr. Jason Luke from University of Pittsburgh Medical Center.
The discussion covered ASCO abstract #9503 Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047), ASCO abstract #9502 Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma and ASCO Abstract #9506 CheckMate 067: 6.5-year outcomes inpatients (pts) with advanced melanoma.
Watch this video for the full discussion:
Our ASCO Panel Series covered six therapeutic areas including melanoma. Click below to read more about them and watch their video analysis.
The advent of precision oncology is marked by many new changes and improvements in diagnostic, prognostic and treatment methods for cancer patients. Researchers looking to bring new drugs to market are now also privy to a vast database of material from previously conducted studies thanks to a push forward in research collaborations and the creation of shared data hubs.